{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T06:17:08Z","timestamp":1794723428183,"version":"4.9.1"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T00:00:00Z","timestamp":1655424000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T00:00:00Z","timestamp":1655424000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Mebendazole (MBZ) is an efficacious anthelmintic with known anti-inflammatory and fibrinolytic properties. In this study, we aimed to explore the protective effects of this FDA-approved drug against DSS-induced colitis in a murine model either alone or in combination with Sulfasalazine (SSZ), a standard therapy for ulcerative colitis. We found that MBZ significantly improved colitis disease activity index as assessed by changes in body weight, degree of stool consistency, rectal bleeding, and prolapse. We also found that MBZ ameliorated the colon histopathological score by attenuating crypt loss, mucosal damage, and inflammation score in colitis tissues. Similarly, DSS-induced colon shortening, colon weight loss, and increase in spleen weight were all abrogated in the presence of MBZ. Moreover, MBZ decreased inflammation, possibly by reducing oxidative stress markers, suppressing inflammatory cell infiltration, and down-regulation of inflammatory genes in colon tissues. Furthermore, MBZ potently reduced fibrosis by decreasing collagen deposition and down-regulating pro-fibrotic genes including Col 1a1 and Col 1a2 in colitis tissue homogenates. In conclusion, our study showed that this broad-spectrum anthelminthic could be repurposed as a novel therapy for ulcerative colitis without any observed side effects, however, regarding the concerns about the potential toxicity of MBZ in UC patients, future experiments on MBZ therapy in other models of UC is needed to completely address the toxicity concerns.<\/jats:p>","DOI":"10.1038\/s41598-022-14420-6","type":"journal-article","created":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T15:03:47Z","timestamp":1655478227000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Mebendazole, an anti-helminth drug, suppresses inflammation, oxidative stress and injury in a mouse model of ulcerative colitis"],"prefix":"10.1038","volume":"12","author":[{"given":"Moein","family":"Eskandari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fereshteh","family":"Asgharzadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Mostafa","family":"Askarnia-faal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamideh","family":"Naimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir","family":"Avan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitra","family":"Ahadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hassan","family":"Vossoughinia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masoumeh","family":"Gharib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atena","family":"Soleimani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niloufar","family":"Naghibzadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gordon","family":"Ferns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikhail","family":"Ryzhikov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Majid","family":"Khazaei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seyed Mahdi","family":"Hassanian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,17]]},"reference":[{"issue":"7351","key":"14420_CR1","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/nature10209","volume":"474","author":"B Khor","year":"2011","unstructured":"Khor, B., Gardet, A. & Xavier, R. J. Genetics and pathogenesis of inflammatory bowel disease. Nature 474(7351), 307\u2013317 (2011).","journal-title":"Nature"},{"issue":"1","key":"14420_CR2","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/s41572-020-0205-x","volume":"6","author":"T Kobayashi","year":"2020","unstructured":"Kobayashi, T. et al. Ulcerative colitis. Nat. Rev. Dis. Primers. 6(1), 74 (2020).","journal-title":"Nat. Rev. Dis. Primers."},{"key":"14420_CR3","doi-asserted-by":"crossref","unstructured":"Abraham BP, Ahmed T, Ali T. Inflammatory bowel disease: pathophysiology and current therapeutic approaches. Gastrointest. Pharmacol. 2017:115\u201346.","DOI":"10.1007\/164_2016_122"},{"key":"14420_CR4","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/B978-0-12-405211-6.00004-8","volume":"59","author":"JB Seidelin","year":"2013","unstructured":"Seidelin, J. B., Coskun, M. & Nielsen, O. H. Mucosal healing in ulcerative colitis: pathophysiology and pharmacology. Adv. Clin. Chem. 59, 101\u2013123 (2013).","journal-title":"Adv. Clin. Chem."},{"issue":"2","key":"14420_CR5","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1002\/path.4118","volume":"229","author":"BS Scales","year":"2013","unstructured":"Scales, B. S. & Huffnagle, G. B. The microbiome in wound repair and tissue fibrosis. J. Pathol. 229(2), 323\u2013331 (2013).","journal-title":"J. Pathol."},{"issue":"11","key":"14420_CR6","doi-asserted-by":"publisher","first-page":"2198","DOI":"10.1097\/MIB.0000000000000080","volume":"20","author":"IO Gordon","year":"2014","unstructured":"Gordon, I. O., Agrawal, N., Goldblum, J. R., Fiocchi, C. & Rieder, F. Fibrosis in ulcerative colitis: mechanisms, features, and consequences of a neglected problem. Inflamm. Bowel Dis. 20(11), 2198\u20132206 (2014).","journal-title":"Inflamm. Bowel Dis."},{"issue":"167","key":"14420_CR7","doi-asserted-by":"publisher","first-page":"167srl-srl","DOI":"10.1126\/scitranslmed.3004700","volume":"5","author":"SL Friedman","year":"2013","unstructured":"Friedman, S. L., Sheppard, D., Duffield, J. S. & Violette, S. Therapy for fibrotic diseases: nearing the starting line. Sci. Transl. Med. 5(167), 167srl-srl (2013).","journal-title":"Sci. Transl. Med."},{"issue":"1","key":"14420_CR8","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1136\/gut.2006.090456","volume":"56","author":"F Rieder","year":"2007","unstructured":"Rieder, F., Brenmoehl, J., Leeb, S., Sch\u00f6lmerich, J. & Rogler, G. Wound healing and fibrosis in intestinal disease. Gut 56(1), 130\u2013139 (2007).","journal-title":"Gut"},{"issue":"5","key":"14420_CR9","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1136\/gut.5.5.437","volume":"5","author":"A Dick","year":"1964","unstructured":"Dick, A., Grayson, M., Carpenter, R. & Petrie, A. Controlled trial of sulphasalazine in the treatment of ulcerative colitis. Gut 5(5), 437 (1964).","journal-title":"Gut"},{"issue":"1","key":"14420_CR10","first-page":"157","volume":"16","author":"DS Rampton","year":"1981","unstructured":"Rampton, D. S. & Sladen, G. E. The effect of sulphasalazine withdrawal on rectal mucosal function and prostaglandin E2 release in inactive ulcerative colitis. Scand. J. Gastroenterol. 16(1), 157\u2013159 (1981).","journal-title":"Scand. J. Gastroenterol."},{"issue":"3","key":"14420_CR11","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/BF02555026","volume":"29","author":"RK Pearl","year":"1986","unstructured":"Pearl, R. K., Nelson, R. L., Prasad, M. L., Orsay, C. P. & Abcarian, H. Serious complications of sulfasalazine. Dis. Colon Rectum 29(3), 201\u2013202 (1986).","journal-title":"Dis. Colon Rectum"},{"issue":"2","key":"14420_CR12","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.crohns.2011.11.001","volume":"6","author":"W Reinisch","year":"2012","unstructured":"Reinisch, W. et al. Recommendations for the treatment of ulcerative colitis with infliximab: a gastroenterology expert group consensus. J. Crohns Colitis 6(2), 248\u2013258 (2012).","journal-title":"J. Crohns Colitis"},{"issue":"2","key":"14420_CR13","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1002\/ibd.20997","volume":"16","author":"GR Lichtenstein","year":"2010","unstructured":"Lichtenstein, G. R. & Rutgeerts, P. Importance of mucosal healing in ulcerative colitis. Inflamm. Bowel Dis. 16(2), 338\u2013346 (2010).","journal-title":"Inflamm. Bowel Dis."},{"key":"14420_CR14","unstructured":"Guidelines for treatment of cystic and alveolar echinococcosis in humans. WHO Informal Working Group on Echinococcosis. Bull. World Health Organ. 1996;74(3):231\u201342."},{"issue":"1","key":"14420_CR15","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1080\/00034983.1992.11812631","volume":"86","author":"T Todorov","year":"1992","unstructured":"Todorov, T. et al. Chemotherapy of human cystic echinococcosis: comparative efficacy of mebendazole and albendazole. Ann. Trop. Med. Parasitol. 86(1), 59\u201366 (1992).","journal-title":"Ann. Trop. Med. Parasitol."},{"issue":"4","key":"14420_CR16","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1136\/adc.66.4.532","volume":"66","author":"J Messaritakis","year":"1991","unstructured":"Messaritakis, J. et al. High mebendazole doses in pulmonary and hepatic hydatid disease. Arch. Dis. Child. 66(4), 532\u2013533 (1991).","journal-title":"Arch. Dis. Child."},{"issue":"9","key":"14420_CR17","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.3390\/cancers11091284","volume":"11","author":"AE Guerini","year":"2019","unstructured":"Guerini, A. E. et al. Mebendazole as a candidate for drug repurposing in oncology: An extensive review of current literature. Cancers 11(9), 1284 (2019).","journal-title":"Cancers"},{"issue":"8","key":"14420_CR18","doi-asserted-by":"publisher","first-page":"12576","DOI":"10.18632\/oncotarget.14990","volume":"8","author":"CM Simbulan-Rosenthal","year":"2017","unstructured":"Simbulan-Rosenthal, C. M. et al. The repurposed anthelmintic mebendazole in combination with trametinib suppresses refractory NRASQ61K melanoma. Oncotarget 8(8), 12576 (2017).","journal-title":"Oncotarget"},{"issue":"1","key":"14420_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-019-55666-x","volume":"9","author":"NS Younis","year":"2019","unstructured":"Younis, N. S., Ghanim, A. M. & Saber, S. Mebendazole augments sensitivity to sorafenib by targeting MAPK and BCL-2 signalling in n-nitrosodiethylamine-induced murine hepatocellular carcinoma. Sci. Rep. 9(1), 1\u201316 (2019).","journal-title":"Sci. Rep."},{"issue":"4","key":"14420_CR20","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1080\/08923973.2017.1320671","volume":"39","author":"K Blom","year":"2017","unstructured":"Blom, K. et al. The anticancer effect of mebendazole may be due to M1 monocyte\/macrophage activation via ERK1\/2 and TLR8-dependent inflammasome activation. Immunopharmacol. Immunotoxicol. 39(4), 199\u2013210 (2017).","journal-title":"Immunopharmacol. Immunotoxicol."},{"issue":"42","key":"14420_CR21","doi-asserted-by":"publisher","first-page":"68571","DOI":"10.18632\/oncotarget.11851","volume":"7","author":"T Williamson","year":"2016","unstructured":"Williamson, T., Bai, R.-Y., Staedtke, V., Huso, D. & Riggins, G. J. Mebendazole and a non-steroidal anti-inflammatory combine to reduce tumor initiation in a colon cancer preclinical model. Oncotarget 7(42), 68571 (2016).","journal-title":"Oncotarget"},{"issue":"14","key":"14420_CR22","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.18632\/oncotarget.28014","volume":"12","author":"T Williamson","year":"2021","unstructured":"Williamson, T. et al. Mebendazole disrupts stromal desmoplasia and tumorigenesis in two models of pancreatic cancer. Oncotarget 12(14), 1326 (2021).","journal-title":"Oncotarget"},{"issue":"2","key":"14420_CR23","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/0006-2952(96)00207-9","volume":"52","author":"H Soto","year":"1996","unstructured":"Soto, H., Mass\u00f3, F., Cano, S. & de Le\u00f3n, L. D. Effects of mebendazole on protein biosynthesis and secretion in human-derived fibroblast cultures. Biochem. Pharmacol. 52(2), 289\u2013299 (1996).","journal-title":"Biochem. Pharmacol."},{"key":"14420_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.taap.2020.115001","volume":"396","author":"X Wang","year":"2020","unstructured":"Wang, X. et al. Mebendazole is a potent inhibitor to chemoresistant T cell acute lymphoblastic leukemia cells. Toxicol. Appl. Pharmacol. 396, 115001 (2020).","journal-title":"Toxicol. Appl. Pharmacol."},{"issue":"12","key":"14420_CR25","doi-asserted-by":"publisher","first-page":"1568","DOI":"10.1038\/s41401-019-0249-1","volume":"40","author":"XH Chen","year":"2019","unstructured":"Chen, X. H. et al. Mebendazole elicits potent antimyeloma activity by inhibiting the USP5\/c-Maf axis. Acta Pharmacol. Sin. 40(12), 1568\u20131577 (2019).","journal-title":"Acta Pharmacol. Sin."},{"key":"14420_CR26","doi-asserted-by":"publisher","first-page":"50","DOI":"10.2119\/molmed.2017.00011","volume":"23","author":"M De Witt","year":"2017","unstructured":"De Witt, M. et al. Repurposing mebendazole as a replacement for vincristine for the treatment of brain tumors. Mol. Med. (Cambridge, Mass). 23, 50\u201356 (2017).","journal-title":"Mol. Med. (Cambridge, Mass)."},{"key":"14420_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2020.117470","volume":"249","author":"F Rahmani","year":"2020","unstructured":"Rahmani, F. et al. Rigosertib potently protects against colitis-associated intestinal fibrosis and inflammation by regulating PI3K\/AKT and NF-\u03baB signaling pathways. Life Sci. 249, 117470 (2020).","journal-title":"Life Sci."},{"issue":"1","key":"14420_CR28","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/nprot.2009.197","volume":"5","author":"CJ Weydert","year":"2010","unstructured":"Weydert, C. J. & Cullen, J. J. Measurement of superoxide dismutase, catalase and glutathione peroxidase in cultured cells and tissue. Nat. Protoc. 5(1), 51\u201366 (2010).","journal-title":"Nat. Protoc."},{"issue":"9","key":"14420_CR29","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1002\/jcp.24568","volume":"229","author":"SM Hassanian","year":"2014","unstructured":"Hassanian, S. M., Dinarvand, P. & Rezaie, A. R. Adenosine regulates the proinflammatory signaling function of thrombin in endothelial cells. J. Cell Physiol. 229(9), 1292\u20131300 (2014).","journal-title":"J. Cell Physiol."},{"key":"14420_CR30","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.jpba.2017.12.056","volume":"151","author":"M Majewsky","year":"2018","unstructured":"Majewsky, M. et al. Systematic identification of suspected anthelmintic benzimidazole metabolites using LC-MS\/MS. J. Pharm. Biomed. Anal. 151, 151\u2013158 (2018).","journal-title":"J. Pharm. Biomed. Anal."},{"key":"14420_CR31","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.jpba.2019.03.048","volume":"171","author":"T Bach","year":"2019","unstructured":"Bach, T., Bae, S., D\u2019Cunha, R., Winokur, P. & An, G. Development and validation of a simple, fast, and sensitive LC\/MS\/MS method for the quantification of oxfendazole in human plasma and its application to clinical pharmacokinetic study. J. Pharm. Biomed. Anal. 171, 111\u2013117 (2019).","journal-title":"J. Pharm. Biomed. Anal."},{"key":"14420_CR32","unstructured":"PubChem [Internet]. Bethesda (MD): National Library of Medicine (US), National Center for Biotechnology Information; 2004-. PubChem Compound Summary for CID 4030, Mebendazole; [cited 2022 Mar. 2]. Available from: https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/Mebendazole."},{"issue":"12","key":"14420_CR33","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1002\/ibd.20986","volume":"15","author":"AM Schoepfer","year":"2009","unstructured":"Schoepfer, A. M. et al. Ulcerative colitis: correlation of the Rachmilewitz endoscopic activity index with fecal calprotectin, clinical activity, C-reactive protein, and blood leukocytes. Inflamm. Bowel Dis. 15(12), 1851\u20131858 (2009).","journal-title":"Inflamm. Bowel Dis."},{"issue":"3\u20134","key":"14420_CR34","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1007\/s00424-017-1958-2","volume":"469","author":"JR Grainger","year":"2017","unstructured":"Grainger, J. R., Konkel, J. E., Zangerle-Murray, T. & Shaw, T. N. Macrophages in gastrointestinal homeostasis and inflammation. Pflugers Arch. 469(3\u20134), 527\u2013539 (2017).","journal-title":"Pflugers Arch."},{"key":"14420_CR35","doi-asserted-by":"publisher","first-page":"2733","DOI":"10.3389\/fimmu.2018.02733","volume":"9","author":"CC Bain","year":"2018","unstructured":"Bain, C. C. & Schridde, A. Origin, differentiation, and function of intestinal macrophages. Front. Immunol. 9, 2733 (2018).","journal-title":"Front. Immunol."},{"issue":"9","key":"14420_CR36","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.3390\/cancers11091284","volume":"11","author":"AE Guerini","year":"2019","unstructured":"Guerini, A. E. et al. Mebendazole as a candidate for drug repurposing in oncology: An extensive review of current literature. Cancers (Basel). 11(9), 1284 (2019).","journal-title":"Cancers (Basel)."},{"issue":"2","key":"14420_CR37","doi-asserted-by":"publisher","first-page":"105","DOI":"10.2174\/187221310791163071","volume":"4","author":"J Wei","year":"2010","unstructured":"Wei, J. & Feng, J. Signaling pathways associated with inflammatory bowel disease. Recent Pat. Inflamm. Allergy Drug Discov. 4(2), 105\u2013117 (2010).","journal-title":"Recent Pat. Inflamm. Allergy Drug Discov."},{"issue":"12","key":"14420_CR38","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1093\/ecco-jcc\/jjx104","volume":"11","author":"ME Wildenberg","year":"2017","unstructured":"Wildenberg, M. E. et al. Benzimidazoles promote anti-TNF mediated induction of regulatory macrophages and enhance therapeutic efficacy in a murine model. J. Crohns Colitis 11(12), 1480\u20131490 (2017).","journal-title":"J. Crohns Colitis"},{"issue":"2","key":"14420_CR39","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/S0016-5085(98)70202-1","volume":"115","author":"G Rogler","year":"1998","unstructured":"Rogler, G. et al. Nuclear factor kappaB is activated in macrophages and epithelial cells of inflamed intestinal mucosa. Gastroenterology 115(2), 357\u2013369 (1998).","journal-title":"Gastroenterology"},{"issue":"4","key":"14420_CR40","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1136\/gut.42.4.477","volume":"42","author":"S Schreiber","year":"1998","unstructured":"Schreiber, S., Nikolaus, S. & Hampe, J. Activation of nuclear factor kappa B inflammatory bowel disease. Gut 42(4), 477\u2013484 (1998).","journal-title":"Gut"},{"key":"14420_CR41","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1111\/j.1749-6632.1998.tb11119.x","volume":"859","author":"MF Neurath","year":"1998","unstructured":"Neurath, M. F. et al. Cytokine gene transcription by NF-kappa B family members in patients with inflammatory bowel disease. Ann. N. Y. Acad. Sci. 859, 149\u2013159 (1998).","journal-title":"Ann. N. Y. Acad. Sci."},{"issue":"11","key":"14420_CR42","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.3109\/10715762.2012.717692","volume":"46","author":"G Jena","year":"2012","unstructured":"Jena, G., Trivedi, P. P. & Sandala, B. Oxidative stress in ulcerative colitis: an old concept but a new concern. Free Radic Res. 46(11), 1339\u20131345 (2012).","journal-title":"Free Radic Res."},{"issue":"7","key":"14420_CR43","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1038\/nm.2807","volume":"18","author":"TA Wynn","year":"2012","unstructured":"Wynn, T. A. & Ramalingam, T. R. Mechanisms of fibrosis: therapeutic translation for fibrotic disease. Nat Med. 18(7), 1028\u20131040 (2012).","journal-title":"Nat Med."},{"key":"14420_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/j.jep.2020.113251","volume":"265","author":"Y Yang","year":"2021","unstructured":"Yang, Y. et al. Dextran sulfate sodium-induced colitis and ginseng intervention altered oral pharmacokinetics of cyclosporine A in rats. J. Ethnopharmacol. 265, 113251 (2021).","journal-title":"J. Ethnopharmacol."},{"issue":"4","key":"14420_CR45","doi-asserted-by":"publisher","first-page":"582","DOI":"10.7326\/0003-4819-91-4-582","volume":"91","author":"JS Keystone","year":"1979","unstructured":"Keystone, J. S. & Murdoch, J. K. Mebendazole. Ann. Intern. Med. 91(4), 582\u2013586 (1979).","journal-title":"Ann. Intern. Med."},{"issue":"4","key":"14420_CR46","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1080\/00034983.1999.11813432","volume":"93","author":"K Vutova","year":"1999","unstructured":"Vutova, K. et al. Effect of mebendazole on human cystic echinococcosis: the role of dosage and treatment duration. Ann. Trop. Med. Parasitol. 93(4), 357\u2013365 (1999).","journal-title":"Ann. Trop. Med. Parasitol."},{"issue":"8","key":"14420_CR47","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1128\/AAC.37.8.1679","volume":"37","author":"A Teggi","year":"1993","unstructured":"Teggi, A., Lastilla, M. G. & De Rosa, F. Therapy of human hydatid disease with mebendazole and albendazole. Antimicrob. Agents Chemother. 37(8), 1679\u20131684 (1993).","journal-title":"Antimicrob. Agents Chemother."},{"issue":"4","key":"14420_CR48","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1016\/0035-9203(82)90151-1","volume":"76","author":"AD Bryceson","year":"1982","unstructured":"Bryceson, A. D. et al. Experience with mebendazole in the treatment of inoperable hydatid disease in England. Trans. R. Soc. Trop. Med. Hyg. 76(4), 510\u2013518 (1982).","journal-title":"Trans. R. Soc. Trop. Med. Hyg."},{"issue":"3","key":"14420_CR49","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1080\/00034983.1992.11812661","volume":"86","author":"C Bartoloni","year":"1992","unstructured":"Bartoloni, C., Tricerri, A., Guidi, L. & Gambassi, G. The efficacy of chemotherapy with mebendazole in human cystic echinococcosis: long-term follow-up of 52 patients. Ann. Trop. Med. Parasitol. 86(3), 249\u2013256 (1992).","journal-title":"Ann. Trop. Med. Parasitol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-14420-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-14420-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-14420-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,25]],"date-time":"2022-11-25T05:36:01Z","timestamp":1669354561000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-14420-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,17]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["14420"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-14420-6","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,17]]},"assertion":[{"value":"14 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"10249"}}